BCAL Diagnostics Limited (BDX.AX)
BCAL Diagnostics Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.06, up 0.00% on the session, giving a market capitalisation of $21.8M. Its beta of 0.81 implies it has historically moved less than the broad market.
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
BCAL Diagnostics Limited is most often compared with the following Healthcare names: